Comparison of half-dose and full-dose gadolinium MR contrast on the enhancement of bone and soft tissue tumors

Skeletal Radiology

Volumn 40, Issue 3, 2011, Pages 327-333

  Costelloe, Colleen M ^a   Murphy Jr , William A ^a   Haygood, Tamara M ^a   Kumar, Rajendra ^a   McEnery, Kevin W ^a   Stafford, R Jason ^a   Roy, Anjali ^b   Bassett Jr , Roland L ^a   Harrell, Robyn K ^a   Madewell, John E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b CANCER TREATMENT CENTERS OF AMERICA   (United States)

Author keywords

Bone and soft tissue tumor; Half dose gadolinium; MRI; Nephrogenic systemic fibrosis; Reduced glomerular filtration rate (GFR); Renal failure

Indexed keywords

GADODIAMIDE; GADOLINIUM PENTETATE;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; BONE TUMOR; CHONDROSARCOMA; CHORDOMA; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DATA BASE; DERMATOFIBROMA; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIFFUSION WEIGHTED IMAGING; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; GIANT CELL TUMOR; HUMAN; IMAGE ANALYSIS; INFORMED CONSENT; KIDNEY CANCER; LIPOSARCOMA; LOW DRUG DOSE; LUNG CANCER; LYMPHOMA; MELANOMA; MUSCULOSKELETAL FUNCTION; MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHEOCHROMOCYTOMA; PRIMARY TUMOR; PRIORITY JOURNAL; RADIOLOGIST; SMALL CELL CARCINOMA; SOFT TISSUE TUMOR;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; CONTRAST MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GADOLINIUM; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SOFT TISSUE NEOPLASMS;

EID: 79953827295     PISSN: 03642348     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00256-010-1028-8     Document Type: Article

References (21)

1. Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006;21:1104-8.
2. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006;17:2359-62. (Pubitemid 44300951)
3. Lee CU, Wood CM, Hesley GK, et al. Large sample of nephrogenic systemic fibrosis cases from a single institution. Arch Dermatol. 2009;145:1095-102.
4. Abujudeh HH, Kaewlai R, Kagan A, et al. Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients. Radiology. 2009;253:81-9.
5. Jimenez SA, Artlett CM, Sandorfi N, et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum. 2004;50:2660-6. (Pubitemid 39062729)
6. Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol. 2003;139:903-6. (Pubitemid 36898926)
7. United, States, Food, and, Drug, Administration. Information for Healthcare Professionals Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging (marketed as Magnevist, MultiHance, Omniscan, OptiMARK, ProHance). http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm142884.htm. Published June 2006, updated December 2006 and May 2007, accessed November 2009. In.
8. Kanal E, Barkovich AJ, Bell C, et al. ACR guidance document for safe MR practices: 2007. AJR Am J Roentgenol. 2007;188:1447-74. (Pubitemid 46866845)
9. Rinck PA, Muller RN. Field strength and dose dependence of contrast enhancement by gadolinium-based MR contrast agents. Eur Radiol. 1999;9:998-1004.
10. Haustein J, Laniado M, Niendorf HP, et al. Administration of gadopentetate dimeglumine in MR imaging of intracranial tumors: dosage and field strength. AJNR Am J Neuroradiol. 1992;13:1199-206.
11. Erlemann R, Reiser MF, Peters PE, et al. Musculoskeletal neoplasms: static and dynamic Gd-DTPA-enhanced MR imaging. Radiology. 1989;171:767-73. (Pubitemid 19134937)
12. Harkens KL, Moore TE, Yuh WT, et al. Gadolinium-enhanced MRI of soft tissue masses. Australas Radiol. 1993;37:30-4. (Pubitemid 23175638)
13. Verstraete KL, Vanzieleghem B, De Deene Y, et al. Static, dynamic and first-pass MR imaging of musculoskeletal lesions using gadodiamide injection. Acta Radiol. 1995;36:27-36.
14. Fletcher BD, Hanna SL, Fairclough DL, Gronemeyer SA. Pediatric musculoskeletal tumors: use of dynamic, contrast-enhanced MR imaging to monitor response to chemotherapy. Radiology. 1992;184:243-8.
15. Erlemann R, Sciuk J, Bosse A, et al. Response of osteosarcoma and Ewing sarcoma to preoperative chemotherapy: assessment with dynamic and static MR imaging and skeletal scintigraphy. Radiology. 1990;175:791-6. (Pubitemid 20191948)
16. Barile A, Caulo M, Zugaro L, Di Cesare E, Gallucci M. Masciocchi C [Staging and re-staging of soft tissue sarcoma using MRI. Usefulness of contrast media]. Radiol Med. 2001;101:444-55.
17. Vanel D, Shapeero LG, De Baere T, et al. MR imaging in the follow-up of malignant and aggressive soft-tissue tumors: results of 511 examinations. Radiology. 1994;190:263-8.
18. Beltran J, Chandnani V, McGhee Jr RA, Kursunoglu-Brahme S. Gadopentetate dimeglumine-enhanced MR imaging of the musculoskeletal system. AJR Am J Roentgenol. 1991;156:457-66.
19. Prince MR, Zhang H, Morris M, et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology. 2008;248:807-16.
20. Lauenstein TC, Salman K, Morreira R, et al. Nephrogenic systemic fibrosis: center case review. J Magn Reson Imaging. 2007;26:1198-203. (Pubitemid 350058286)
21. Martin DR, Krishnamoorthy SK, Kalb B, et al. Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols. J Magn Reson Imaging. 2010;31:440-6.